TY - JOUR
T1 - Genetic heterogeneity in acute myeloid leukemia
T2 - Maximizing information flow from MuLV mutagenesis studies
AU - Largaespada, D. A.
PY - 2000
Y1 - 2000
N2 - The study of myeloid leukemia induced by slow transforming murine leukemia viruses (MuLV) in the laboratory mouse has led to discovery of many important genes with critical roles in regulating the growth, death, lineage determination and development of hematopoietic precursor cells. This review provides an overview of the susceptible strains and virus isolates that cause acute myeloid leukemia (AML) in mice. In addition, newer methodologies, involving the use of the polymerase chain reaction, that have been used to identify cancer genes mutated by proviral insertion in mouse models, will be discussed. As cancer is a multi-gene disease, a system in which pairs of oncogenic mutations are classified as redundant, neutral or synergistic is described. The potential to combine MuLV mutagenesis with recent advances in mouse transgenesis in order to model specific forms of myeloid leukemia or genetic pathways common in human AML will be discussed. Finally, a general strategy for maximizing these genetically rich models to foster a better understanding of AML physiology and developing therapies is proposed.
AB - The study of myeloid leukemia induced by slow transforming murine leukemia viruses (MuLV) in the laboratory mouse has led to discovery of many important genes with critical roles in regulating the growth, death, lineage determination and development of hematopoietic precursor cells. This review provides an overview of the susceptible strains and virus isolates that cause acute myeloid leukemia (AML) in mice. In addition, newer methodologies, involving the use of the polymerase chain reaction, that have been used to identify cancer genes mutated by proviral insertion in mouse models, will be discussed. As cancer is a multi-gene disease, a system in which pairs of oncogenic mutations are classified as redundant, neutral or synergistic is described. The potential to combine MuLV mutagenesis with recent advances in mouse transgenesis in order to model specific forms of myeloid leukemia or genetic pathways common in human AML will be discussed. Finally, a general strategy for maximizing these genetically rich models to foster a better understanding of AML physiology and developing therapies is proposed.
KW - Acute myeloid leukemia
KW - Molecular cloning
KW - Mouse
KW - MuLV
UR - http://www.scopus.com/inward/record.url?scp=0033920886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033920886&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2401852
DO - 10.1038/sj.leu.2401852
M3 - Review article
C2 - 10914539
AN - SCOPUS:0033920886
SN - 0887-6924
VL - 14
SP - 1174
EP - 1184
JO - Leukemia
JF - Leukemia
IS - 7
ER -